EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment

Bhaumik Shah, Muhammad Hussain, Anjali Seth

Current Issues in Molecular Biology · 08.08.2025 · 47 (8) · 638

DOI: 10.3390/cimb47080638 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 08.08.2025. Verfasst von Bhaumik Shah und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19121, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homologous recombination deficiency (HRD) is a pivotal biomarker in precision oncology, driving therapeutic strategies for ovarian and breast cancers through impaired DNA double-strand break repair. This narrative review synthesizes recent advances (2021–2025) in HRD’s biological basis, prevalence, detection methods, and clinical implications, focusing on high-grade serous ovarian carcinoma (HGSOC; ~50% HRD prevalence) and triple-negative breast cancer (TNBC; 50–70% prevalence). HRD arises from genetic (BRCA1/2, RAD51C/D, PALB2) and epigenetic alterations (e.g., BRCA1 methylation), leading to genomic instability detectable via scars (LOH, TAI, LST) and mutational signatures (e.g., COSMIC SBS3). Advanced detection integrates genomic assays (Myriad myChoice CDx, Caris HRD, FoundationOne CDx), functional assays (RAD51 foci), and epigenetic profiling, with tools like HRProfiler and GIScar achieving >90% sensitivity. HRD predicts robust responses to PARP inhibitors (PARPi) and platinum therapies, extending progression-free survival by 12–36 months in HGSOC. However, resistance mechanisms (BRCA reversion, SETD1A/EME1, SOX5) and assay variability (60–70% non-BRCA concordance) pose challenges. We propose a conceptual framework in Section 10, integrating multi-omics, methylation analysis, and biallelic reporting to enhance detection and therapeutic stratification. Regional variations (e.g., Asian cohorts) and disparities in access underscore the need for standardized, cost-effective diagnostics. Future priorities include validating novel biomarkers (SBS39, miR-622) and combination therapies (PARPi with ATR inhibitors) to overcome resistance and broaden HRD’s applicability across cancers.

Schlagwörter

Stichwörter der Autor:innen

BRCA1/2PARP inhibitors (PARPi)breast cancergenomic scarshomologous recombination deficiency (HRD)liquid biopsyloss of heterozygosity (LOH)multi-omicsovarian cancerprecision oncology

Autor:innen und Institutionen

  • Department of Pathology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA 19121, USA.
  • Department of Pathology, Temple University Hospital, Temple Health, 3401 N Broad St., Philadelphia, PA 19140, USA.

Zitieren

APA

Shah, B., Hussain, M., & Seth, A. (2025). Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment. Current Issues in Molecular Biology, 47(8), 638. https://doi.org/10.3390/cimb47080638

Vancouver

Shah B, Hussain M, Seth A. Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment. Current Issues in Molecular Biology. 2025;47(8):638. doi:10.3390/cimb47080638

BibTeX
@article{Shah2025,
  author = {Shah, Bhaumik and Hussain, Muhammad and Seth, Anjali},
  title = {Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and Treatment},
  journal = {Current Issues in Molecular Biology},
  year = {2025},
  volume = {47},
  number = {8},
  pages = {638},
  doi = {10.3390/cimb47080638}
}
Kostenlos starten →